1. Caffeic acid alleviates skeletal muscle atrophy in 5/6 nephrectomy rats through the TLR4/MYD88/NF-kB pathway.
- Author
-
He J, He Z, Wang H, Zhang C, Pei T, Yan S, Yan Y, Wang F, Chen Y, Yuan N, Wang M, and Xiao W
- Subjects
- Animals, Male, Rats, Cytokines metabolism, Muscle, Skeletal drug effects, Muscle, Skeletal pathology, Muscle, Skeletal metabolism, Nephrectomy adverse effects, NF-kappa B metabolism, Oxidative Stress drug effects, Rats, Sprague-Dawley, Toll-Like Receptor 4 metabolism, Caffeic Acids pharmacology, Muscular Atrophy drug therapy, Muscular Atrophy pathology, Muscular Atrophy etiology, Muscular Atrophy prevention & control, Muscular Atrophy metabolism, Myeloid Differentiation Factor 88 metabolism, Renal Insufficiency, Chronic drug therapy, Renal Insufficiency, Chronic metabolism, Renal Insufficiency, Chronic pathology, Signal Transduction drug effects
- Abstract
Skeletal muscle atrophy is a common complication of chronic kidney disease (CKD) that affects the quality of life and prognosis of patients. We aimed to investigate the effects and mechanisms of caffeic acid (CA), a natural phenolic compound, on skeletal muscle atrophy in CKD rats. Male Sprague-Dawley rats underwent 5/6 nephrectomy (NPM) and were treated with CA (20, 40, or 80 mg/kg/day) for 10 weeks. The body and muscle weights, renal function, hemoglobin, and albumin were measured. The histological, molecular, and biochemical changes in skeletal muscles were evaluated using hematoxylin-eosin staining, quantitative real-time PCR, malondialdehyde/catalase/superoxide dismutase/glutathione level detection, and enzyme-linked immunosorbent assay. Western blotting and network pharmacology were applied to identify the potential targets and pathways of CA, CKD, and muscle atrophy. The results showed that CA significantly improved NPM-induced muscle-catabolic effects, reduced the expression of muscle atrophy-related proteins (muscle atrophy F-box and muscle RING finger 1) and proinflammatory cytokines (interleukin [IL]-6, tumor necrosis factor-alpha, and IL-1β), and attenuated muscle oxidative stress. Network pharmacology revealed that CA modulated the response to oxidative stress and nuclear factor kappa B (NF-κB) signaling pathway and that Toll-like receptor 4 (TLR4) was a key target. In vivo experiment confirmed that CA inhibited the TLR4/myeloid differentiation primary response 88 (MYD88)/NF-kB signaling pathway, reduced muscle iron levels, and restored glutathione peroxidase 4 activity, thereby alleviating ferroptosis and inflammation in skeletal muscles. Thus, CA might be a promising therapeutic agent for preventing and treating skeletal muscle atrophy in CKD by modulating the TLR4/MYD88/NF-κB pathway and ferroptosis., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF